Duloxetine is currently approved by the FDA for pain in fibromyalgia. It is contraindicated in patients who are taking or have taken monoamine oxidase inhibitors within the previous 2 weeks. Duloxetine has been shown to improve pain in fibromyalgia, irrespective of comorbid depression. It is a potent inhibitor of neuronal serotonin and norepinephrine reuptake. Its antidepressive action is theorized to be due to serotonergic and noradrenergic potentiation in the central nervous system. It is indicated for fibromyalgia in adults and adolescents aged 13-17 years. The initial dose is 30 mg/d for 1 week to allow for adjustment before increasing to 60 mg/d. No additional benefit has been shown with doses > 60 mg.
Learn more about pharmacotherapy for fibromyalgia.
This Fast Five Quiz was excerpted and adapted from the Medscape article Fibromyalgia.
Follow Medscape on Facebook, Twitter, Instagram, and YouTube
Credits:
Lead image: Science Source
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Herbert S. Diamond. Fast Five Quiz: Fibromyalgia Key Aspects - Medscape - Feb 16, 2022.
